Train-of-Four Monitoring: Complete Buying Guide 2026

Train-of-four (TOF) monitoring is no longer optional. Residual neuromuscular block (rNMB) can affect up to 33% of patients without monitoring (1). As hospitals align with updated guidelines and reduce complications, choosing the right TOF monitor is a critical decision for clinicians and procurement teams.

The 2023 American Society of Anesthesiologists (ASA) practice guidelines mark a clear shift in neuromuscular monitoring standards (2): 

1. Quantitative monitoring is strongly recommended over qualitative assessment 
2. Confirm a TOF ratio ≥0.9 before extubation

These changes raise the standard of care. Facilities relying on peripheral nerve stimulators (PNS) and subjective assessment are not aligned with guidelines, as qualitative methods cannot reliably detect rNMB in the critical recovery range.

As a result, guideline adherence is increasingly tied to:

• Patient safety
• Complication rates
• Institutional quality reporting 

For hospitals, this is not just clinical preference, it is a compliance and risk management issue.

The core limitation of qualitative monitoring is simple: it cannot detect what matters most.

Fade is not reliably visible until the TOF ratio drops below 0.4, creating a “blind zone” from 0.4 to 0.9 where patients may appear recovered but remain impaired.

Clinical impact:

• 40–60% postoperative residual curarization (PORC) incidence with qualitative monitoring (3) 
• 0% rNMB achievable with quantitative monitoring (4) 

*Calculated as 1-Bias vs. MMG

Procurement decisions should focus on total cost of ownership, driven by drug use, complications, and downstream resource utilization.

1. Drug Utilization and Reversal Cost Reduction

Quantitative monitoring changes reversal agents use:

• ~20% of patients achieve spontaneous recovery without reversal (8) 
• 70% reduction in reversal drug costs (4) 
• Sugammadex dosing variability without monitoring: 
  • 87% overdosed (9) 
  • 13% underdosed (9) 

Result: wasted drug spend and increased patient risk.

2. Residual Block Reduction and Risk Avoidance

• High rNMB rates persistent without monitoring (10-11)
• Near zero rNMB achieved with EMG-based monitoring (4)

Impact: improved patient safety, recovery quality, and institutional quality metrics.

3. Postoperative Pulmonary Complication (PPC) Reduction (Largest Cost Driver)

• PPCs remain common without monitoring (12) 
• Risk reduced from ~11.3% to ~3.5% with quantitative protocols (13-15) 

Each PPC drives:

• Increased length of stay (16) 
• Higher ICU admission risk (12) 
• Significant incremental cost (17-19) 

4. ICU Utilization and Escalation Costs

• rNMB linked to PACU complications and unplanned ICU admissions (12) 
• ICU/ARDS care represents some of the highest-cost events (17) 

Avoiding rNMB reduces ICU escalation and prolonged recovery.

5. Total Economic Impact at Scale

Combined impact:

• Lower drug spend 
• Fewer PPCs
• Reduced ICU utilization 

At 8,000–10,000 NMBA cases annually:

• ~ $370,000 annual drug savings (8)
• Multi-million-dollar savings when complications are included 

Bottom line: Quantitative TOF monitoring is a high-ROI clinical intervention that reduces cost, risk, and variability.

“Bringing the next-generation TetraGraph into our community hospital has transformed how we manage neuromuscular block.

It has improved patient safety, standardized our practices, and reduced our annual drug spend by more than $100,000.” 

- Dr. Aaron Persinger,
Anesthesiologist, Boulder Valley Anesthesiology Medical Director, UCHealth Broomfield Anesthesiology Medical Director, Pre-Anesthesia Testing Clinic, UCHealth Broomfield

Quantitative TOF monitoring is not a capital expense. It is a high-ROI clinical intervention that reduces variability, improves outcomes, and lowers total cost of care.

Please note: This page is intended for healthcare professionals. It is primarily tailored to the U.S. market, but may also be relevant for other regions.